CD4 and Autoimmunity: Taken together, these in vivo data suggest that HP1γ reduces the susceptibility of human CD4+ T cells to immunosuppressive signals, and that targeting this molecule could be clinically relevant for repressing pathogenic T cell responses in bone marrow transplanted individuals or in patients suffering from autoimmunity.